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Peptidylarginine deiminases, or PADs, convert arginine residues to the non-ribosomally
encoded amino acid citrulline in a variety of protein substrates. PAD4 is expressed in
granulocytes and is essential for the formation of neutrophil extracellular traps (NETs) via
PAD4-mediated histone citrullination. Citrullination of histones is thought to promote NET
formation by inducing chromatin decondensation and facilitating the expulsion of chromoso-
mal DNA that is coatedwith antimicrobial molecules. Numerous stimuli have been reported
to lead to PAD4 activation and NET formation. However, how this signaling process pro-
ceeds and how PAD4 becomes activated in cells is largely unknown. Herein, we describe
the various stimuli and signaling pathways that have been implicated in PAD4 activation and
NET formation, including the role of reactive oxygen species generation.To provide a foun-
dation for the above discussion, we ﬁrst describe PAD4 structure and function, and how
these studies led to the development of PAD-speciﬁc inhibitors. A comprehensive survey
of the receptors and signaling pathways that regulate PAD4 activation will be important for
our understanding of innate immunity, and the identiﬁcation of signaling intermediates in
PAD4 activation may also lead to the generation of pharmaceuticals to target NET-related
pathogenesis.
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THE PEPTIDYL ARGININE DEIMINASE FAMILY
The mammalian genome encodes 20 natural amino acids; how-
ever, this diversity is greatly increased by posttranslational modi-
ﬁcation of the original set to yield more than one hundred unique
amino acids (Uy andWold, 1977). Citrullination, or deimination,
is the posttranslational modiﬁcation of an arginine to a citrulline
residue. Hydrolysis of the guanidino group of the arginine yields
a ureido group and the loss of an ammonia (Figure 1). Citrul-
lination is catalyzed by the peptidyl arginine deiminase family
of enzymes, or PADs. This process results in the loss of positive
charge and an approximately 1 Da increase in mass. While this
modiﬁcation seems quite modest, the loss of positive charge, and
hydrogen bond acceptors, can have dramatic effects on cell signal-
ing because these types of interactions are critical for stabilizing
protein–protein, protein–DNA, and protein–RNA interactions.
Additionally, this PTM may disrupt intra-molecular interactions,
which could trigger major conformational changes in a protein,
potentially altering intermolecular interactions and decreasing
protein stability (Vossenaar et al., 2003).
Five PAD enzymes are expressed in humans and mice, and
the major difference between these isozymes appears to be tis-
sue localization. PADs 1, 3, and 6 are expressed in the skin and
uterus, hair follicles, and egg, ovary and embryo, respectively
(Vossenaar et al., 2003; Wang et al., 2012). PAD4 expression has
been reported in granulocytes, as well as some cancerous cell lines
and tumors (Vossenaar et al., 2003; Chang et al., 2009; Jones et al.,
2009; Hemmers et al., 2011; Wang et al., 2012), and most recently
in mammalian oocytes and the preimplantation embryo (Brah-
majosyula and Miyake, 2011). PAD2 has a much broader tissue
expression proﬁle and can be found in the CNS, skeletal muscle,
and cells of the immune system (Vossenaar et al., 2003). PADs 1,
2, and 4 are the only PADs expressed in the hematopoietic lineage,
and, thus, are especially of immunological interest.
PADI genes, encoding the PAD enzymes, are located in a
single gene cluster on chromosome 1p36.1 in humans and chro-
mosome 4pE1 in mice (Vossenaar et al., 2003). The regions
encoding the PADI locus in humans and mice span 334.7 and
230.4 kb, respectively (Vossenaar et al., 2003). All PAD enzymes
are highly conserved, sharing at least 50% sequence homology
among isozymes and 70% or greater homology of each vertebrate
ortholog (Vossenaar et al., 2003). Eighteen per cent sequence iden-
tity is shared among all PADs (Vossenaar et al., 2003). Catalysis by
all of these enzymes is calcium dependent, and, at least in vitro,
requires calcium concentrations that are higher than that available
in homeostatic cytoplasm, indicating calcium ﬂux or a calcium-
producing event is necessary to induce activity (Arita et al., 2004;
Kearney et al., 2005; Raijmakers et al., 2007; Knuckley et al.,
2010). Alternatively, a PTM or interacting protein may decrease
the calcium concentration required for activation to physiologic
levels.
PAD4
Of all of the PADs, PAD4 is of speciﬁc interest because of its
importance in innate immunity and its putative role in a vari-
ety of pathogenic states, including autoimmune diseases, such
as rheumatoid arthritis (RA), multiple sclerosis (MS), ulcerative
colitis (UC), and systemic lupus erythematosus (SLE), and other
inﬂammatory conditions, such as sepsis and thrombosis (Jones
et al., 2009).Many autoantibodies inRAare directed against citrul-
linated proteins. In fact, the presence of anti-citrullinated protein
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FIGURE 1 | Conversion of arginine into citrulline. Peptidylarginine
deiminase (PAD) enzymes convert an arginine residue into citrulline.
antibodies (ACPA) is a better predictor of RA than rheumatoid
factor (Vossenaar et al., 2003), and, in 2011, ACPA were included
in the new classiﬁcation criteria for RA (Willemze et al., 2012). A
genome-wide association study identiﬁed a PAD4 haplotype that
is associated with RA in a Japanese population, albeit with a low
odds ratio (OR = 1.14; Suzuki et al., 2003). The mutations in
the PAD4 gene appear to confer prolonged stability to the tran-
script, leading to a model where increased expression of PAD4 in
these populations would favor the generation of citrullinated self-
epitopes to prime the autoimmune response (Suzuki et al., 2003).
Though this association has been conﬁrmed in other Asian popu-
lations, it has not been replicated in studies using patients from all
Western European populations, indicating that the RA-associated
PAD4 haplotype found in Asian RA patients can not explain the
presence of ACPA’s in all ethnicities (Klareskog et al., 2008). Inter-
estingly, the PAD4 RA-associated disease haplotype has also been
found in some Japanese patients with UC (Chen et al., 2008). MS
patients have increased levels of the citrullinated form of myelin
basic protein (Wood et al., 1996; Moscarello et al., 2007), and both
PAD2 and PAD4 are overexpressed in the brains of MS patients
(Wood et al., 2008). Finally, as will be discussed later in this review,
in response tomicrobes, neutrophils can extrude their nuclear con-
tents to form antimicrobial neutrophil extracellular traps (NETs;
Brinkmann and Zychlinsky, 2007). Since PAD4 is essential for the
formationof NETs (Li et al., 2010;Hemmers et al., 2011), PAD4has
also been implicated in NET-related pathologies, such as SLE and
thrombosis, where NETs presumably promote deleterious inﬂam-
matory responses (Kessenbrock et al., 2009; Logters et al., 2009;
Fuchs et al., 2010; Hakkim et al., 2010; Garcia-Romo et al., 2011;
Villanueva et al., 2011). Thus, PAD4 may be a relevant target for
several disease indications.
PAD4 is a 74 kDa protein that exists as a head-to-tail dimer
(Arita et al., 2004; Liu et al., 2011). Each monomer consists of two
N-terminal immunoglobulin (Ig) domains, formed by Ig subdo-
main 1, which contains nine β-sheets, and Ig subdomain 2, which
contains 10 β-sheets and four short α-helices. The C-terminal cat-
alytic domain adopts the α/β propeller fold that is characteristic of
the deiminase superfamily (Shirai et al., 2001; Arita et al., 2004).
The C-terminal catalytic domain is themost highly conserved area
of the molecule (Vossenaar et al., 2003), suggesting that the active
sites are likely quite similar among PADs. While a high degree of
conservation exists among PADs, PAD4 is the only family member
to contain a classic nuclear localization sequence (56-PPAKKKST-
63), found in Ig1 near the N-terminus, and, thus, is trafﬁcked to
the nucleus (Nakashima et al., 2002; Vossenaar et al., 2003; Arita
et al., 2004). However, it is worth noting that recent data indicates
that other PADs, most notably PAD2, are localized to the nucleus
(Zhang et al., 2012).
PAD4 binds ﬁve calcium molecules, designated Ca1–Ca5, in
a cooperative manner (Arita et al., 2004; Kearney et al., 2005; Liu
et al., 2011). Ca1 and Ca2 bind in the C-terminal catalytic domain,
and their binding induces major conformational changes that
move several active site residues into positions that are competent
for catalysis (Arita et al., 2004). This calcium-induced formation of
the active site is unique to the PADs, and represents a novel mech-
anism of enzyme activation (Arita et al., 2004). Calcium binding
also induces large structural changes in the N-terminus of the pro-
tein. For example, binding of Ca3, Ca4, and Ca5, along with two
water molecules, induces the formation of the a1 α-helix, which
is disordered in the apoenzyme (Arita et al., 2004). These confor-
mational changes may provide, or remove, docking sites for other
proteins, which may serve to further regulate PAD activity.
BIOCHEMICAL ACTIVATION OF PAD4
While it is unknown whether all PAD enzymes are capable of mul-
timerizing, the dimer has been suggested to be required for PAD4
activity (Arita et al., 2004; Liu et al., 2011). However, the effects
on enzyme activity and the calcium dependence of the enzyme
are relatively minor (approximately twofold), and we routinely
see robust enzyme activity at concentrations of protein that are
an order of magnitude below the Kd of the dimer (Kearney et al.,
2005). Nevertheless, dimer formation may represent a possible
regulatory mechanism (Liu et al., 2011). Dimerization is medi-
ated by both hydrophobic interactions and salt bridges between
adjacent monomers (Arita et al., 2004; Liu et al., 2011).
The PADs display limited substrate speciﬁcity and citrullinate
many proteins in vitro, preferring to modify arginine residues
present in unstructured regions; the rate of substrate turnover
is inversely proportional to the structural order of the substrate
(Arita et al., 2006; Knuckley et al., 2010). Structurally, PAD4 inter-
acts with the backbone atoms surrounding the site deimination,
i.e., R-2, R-1, R0, and (R + 1), with few, if any, contacts with
the side chains (Arita et al., 2006). The only requirement appears
to be a small side chain at the R-2 position so as to avoid steric
contacts with the active site (Arita et al., 2006). Upon binding to
PAD4 the backbone of the substrate adopts a β-turn-like con-
formation within the substrate binding cleft (Arita et al., 2006),
thereby explaining why the enzymes show such a high level of
substrate promiscuity. In contrast to the situation in vitro, the
PADs are believed to show greater substrate speciﬁcity in vivo.
Presumably, interacting proteins modulate the substrate speci-
ﬁcity of the enzyme or spatially target the enzyme to speciﬁc
regions of the cell. For example, PAD4 is present in the nucleus
and may be targeted to chromatin where it citrullinates a number
of nuclear proteins, including the histones and protein arginine
methyltransferase 1 (PRMT1; Vossenaar et al., 2003; Slack et al.,
2011b). Although PAD4 was reported to convert monomethylated
arginine residues to citrulline (Wang et al., 2004), thismodiﬁcation
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occurs at rates that are 102- to 103-fold slower than an unmodi-
ﬁed arginine, suggesting that the, so-called “demethylimination”
reaction is not physiologically relevant (Hidaka et al., 2005; Kear-
ney et al., 2005; Raijmakers et al., 2007; Thompson and Fast, 2006)
and that citrullination simply antagonizes arginine methylation as
originally suggested by Cuthbert et al. (2004).
In addition to the aforementioned protein substrates, PAD4,
as well as the other PADs, autocitrullinate at several sites on the
enzyme (Andrade et al., 2010; Mechin et al., 2010; Slack et al.,
2011a). Although autocitrullination has been reported to directly
modulate PAD4 activity (Andrade et al., 2010;Mechin et al., 2010),
in our hands, this self-modiﬁcation has no direct effect on enzyme
activity, but it does appear to modulate protein–protein inter-
actions (Slack et al., 2011b). For example, Slack et al. (2011b)
demonstrated that citrullination of PAD4 reduces its ability to
interact with PRMT1 and histone deacetylase (HDAC) 1, perhaps
modulating its ability to alter gene transcription.
PAD MECHANISM AND INHIBITION
Given the substrate promiscuity of the PADs, it is unsurprising
that the PADs also citrullinate a number of smallmolecule arginine
mimics, including benzoyl arginine ethyl ester (BAEE) andbenzoyl
arginine amide (BAA). In fact, these compounds have served as
important mechanistic probes of PAD4 catalysis and provided the
molecular scaffold for the construction of the ﬁrst highly potent
PAD4 inhibitors. Below we highlight key mechanistic insights that
guided the design of these inhibitors.
Brieﬂy, there are four key catalytic residues, Asp350, His471,
Asp473, and Cys645. Asp473 binds to both ω-nitrogens and
Asp350 coordinates to one ω-nitrogen and the δ-nitrogen
(Figure 2A). Cys645 and His471 lie on opposite sides of the
guanidinium group and are appropriately positioned to pro-
mote catalysis via nucleophilic attack on the guanidinium carbon
(Cys645) and protonation of the developing tetrahedral interme-
diate (His471; Figure 2B). Collapse of this intermediate leads
to the loss of ammonia and the formation of the stable S-alkyl
thiouronium intermediate that is subsequently hydrolyzed via a
second tetrahedral intermediate to form citrulline; His471 likely
activates the water molecule for nucleophilic attack (Figure 2B).
Mechanistic studies (Knuckley et al., 2007, 2010), including muta-
genesis, pH rate proﬁle, solvent isotope effects, and solvent
viscosity effects, as well as crystal structures of PAD4 bound to
several substrates (i.e., BAA;Arita et al., 2006), and histoneH3 and
histoneH4 tail analogs; Arita et al., 2004,2006), and inhibitors (i.e.,
F-amidine, Cl-amidine, o-F-amidine, o-Cl-amidine, and TDFA;
Luo et al., 2006a; Causey et al., 2011; Jones et al., 2012), provide
strong support for the above mechanism and helped drive our
thoughts about inhibitor design. For example, the presence of a
reactive active site Cys prompted us to consider the synthesis of
irreversible inhibitors (Knuckley et al., 2007, 2010). Additionally,
the fact that mono-methylated arginine residues were exception-
ally poor PAD substrates, as well as the steric restraints of the
active site (Arita et al., 2004; Kearney et al., 2005; Raijmakers et al.,
2007), told us that the reactive moiety would have to be relatively
isosteric with respect to the substrate guanidinium. Furthermore,
mutagenesis studies on the two active site aspartyl groups in PAD4,
Asp350 and Asp473, showed that these residues are critical for
FIGURE 2 | (A) PAD4 in complex with Histone H4 1–5 (SGRGK). PAD4
active site residue side chains are colored gray (D350, H471, D473, C645A)
and residues that are involved in binding the H4 1–5 backbone and S1 are
colored yellow (Q346,W347, R347). N-terminally acetylated H4 1–5 is
shown in cyan with Arginine 3 bound in the PAD4 active site. Polar residue
interactions between PAD4 and H4 1–5 are indicated by dashed lines. The
mutation of the active site cysteine residue (C645) to an alanine (C645A)
was necessary to achieve substrate binding in the crystal structure as
described in Arita et al. (2006). Figure was created from the structure ﬁled
under PDB code 2dey. (B) Proposed catalytic mechanism for PAD4. (C)
Haloacetamidine-based inhibitors targeting the PAD isozymes.
catalysis (Knuckley et al., 2007), indicating that proper position-
ing, hydrogen bonding, and electrostatic interactions between
these residues and the substrate guanidinium are critical deter-
minants for efﬁcient substrate turnover, and would have to be
maintained for efﬁcient enzyme inactivation. As such, we initially
focused our efforts on synthesizing F-amidine and Cl-amidine
(Figure 2C), two haloacetamidine-containing compounds that we
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hypothesized, and later conﬁrmed, would inactivate the PADs by
alkylating Cys645 (Luo et al., 2006a,b). These initial inhibitors,
F-amidine and Cl-amidine, as well as our second generation com-
pounds o-F-amidine, o-Cl-amidine, and TDFA (Knuckley et al.,
2010; Causey et al., 2011), which show enhanced potency and
selectivity, are bioavailable and have been used to show that
the PADs play important roles in controlling gene transcription
(Li et al., 2008; Yao et al., 2008; Jones et al., 2012; Zhang et al.,
2011, 2012), fertility (Kan et al., 2012), differentiation (Slack et al.,
2011c), and NET formation (Wang et al., 2009; Li et al., 2010).
Additionally, Cl-amidine, or a Cl-amidine analog, decrease dis-
ease severity in animal models of RA, UC, nerve damage, and
cancer (Chumanevich et al., 2011; Lange et al., 2011; Willis et al.,
2011; Wang et al., 2012). Speciﬁcally, we were the ﬁrst to show
that the PAD inhibitor, Cl-amidine dose dependently decreased
inﬂammation by up to 55% in the mouse collagen-induced
arthritis (CIA) model of RA. Concomitant with the decreased
severity there were signiﬁcant decreases in the levels of citrulli-
nated proteins, complement deposition, and epitope spreading
(Willis et al., 2011). Similar dose-dependent effects were observed
in the dextran sodium sulfate (DSS) model of UC where dosing
of up to 75 mg/kg after the onset of disease led to signiﬁcant
reductions in weight loss, inﬂammation score, and colon length-
ening (Chumanevich et al., 2011). The effects of Cl-amidine on
nerve damage was examined in a chick embryo model of spinal
cord injury where treatment with Cl-amidine reduced the abun-
dance of deiminated histone 3, consistent with inhibition of PAD
activity, and signiﬁcantly reduced apoptosis and tissue loss fol-
lowing injury at embryonic day 15 (Lange et al., 2011). Finally,
Wang et al. (2012) showed that a Cl-amidine analog, YW3-56,
decreased tumor growth in a mouse sarcoma S-180 cell-derived
solid tumor model and that additive effects on growth inhibition
were observed when this compound was combined with the his-
tone deacetylase inhibitor SAHA.We have observed similar effects
with Cl-amidine in xenografts model of ductal carcinoma in situ
(McElwee et al., 2012).
THE FUNCTION OF PAD4 IN NEUTROPHILS
Neutrophils are terminally differentiated granulocytes, which dif-
ferentiate from hematopoietic stem cells in the bone marrow, and
make up to 75% of white blood cells in the circulation (Ermert
et al., 2009b). Mature neutrophils are released into circulation,
where they have a very short life span of several hours to one day
before undergoing apoptosis (Borregaard, 2010). Neutrophils are
an important component of the innate immune system and form
theﬁrst line of defense against invading pathogens, such as bacteria
and fungi (Borregaard, 2010). Neutrophils contain an arsenal of
antimicrobial proteins and peptides in primary (or azurophilic),
secondary (or speciﬁc), and tertiary granules. Primary granules are
mostly composed of proteases, such as myeloperoxidase and neu-
trophil elastase (NE), and antimicrobial peptides, such as defensins
(Ermert et al., 2009b). Secondary and tertiary granules contain
lactoferrin and gelatinase, respectively (Mantovani et al., 2011).
Secretory granules also harbor stores of membrane proteins, such
as the NADPHoxidasemachinery (Nox; Borregaard, 2010), which
can be trafﬁcked to the surface of the cell quickly when neces-
sary. In response to chemoattractants, neutrophils are guided to
areas of infection, where they respond with several effector mech-
anisms to invading pathogens, including phagocytosis, release of
bactericidal products, and ROS production (Borregaard, 2010).
Neutropenia, or the state of having too few neutrophils, leads
to extreme immunosuppression and susceptibility to bacterial
infections, which can be fatal (Janeway, 2005).
In 2004, Brinkmann et al. (2004) recognized the formation of
NET structures, which were extruded by neutrophils in response
to bacteria. NETs are composed of nuclear DNA that are dec-
orated with a variety of nuclear and granular proteins, actively
thrown out into the extracellular space, and result in death of the
NET-producing cell (Brinkmann et al., 2004). Cell death by this
mechanism is unique from apoptosis and necrosis and has been
termed “NETosis”(Gupta et al., 2010). NETs ensnare extracellular
bacteria, which are killed by the inherent antimicrobial proper-
ties of NET-associated proteins, such as histones (Parseghian and
Luhrs, 2006), NE (Papayannopoulos and Zychlinsky, 2009), and
lactoferrin (Papayannopoulos and Zychlinsky, 2009). These struc-
tures represent a novel method for pathogen killing, independent
of both degranulation and phagocytosis, and have been shown to
effectively kill a variety of pathogens, including bacteria, fungi,
and protozoa (Papayannopoulos and Zychlinsky, 2009; Remijsen
et al., 2011a). NETs have also been reported to occur in response to
viral infection; however, they not appear to show any observable
anti-viral capabilities (Hemmers et al., 2011). NETs may represent
a killing mechanism for pathogens too large for the neutrophil
to phagocytose, such as fungal hyphae or helminthes (Urban
et al., 2006). Interestingly, bacteria have adapted defense mecha-
nisms to NET formation. For example, the Group A Streptococcus
express a DNase enzyme that can degrade NETs (Buchanan et al.,
2006), and Pseudomonas aeruginosa expresses surface molecules
that can prevent neutrophil activation and NET formation
(Khatua et al., 2012).
Histone citrullination is thought to promoteNET formation by
inducing chromatin decondensation and facilitating the expulsion
of chromosomal DNA coated with antimicrobial molecules (Neeli
et al., 2008; Wang et al., 2009; Li et al., 2010). In fact, chemical
inhibition of PAD4 activity signiﬁcantly reduces histone decon-
densation and NET formation in response to either the calcium
ionophore ionomycin or the bacterium Shigella ﬂexneri (Wang
et al., 2009). Our group and the Wang group have independently
created PAD4-deﬁcientmice (Li et al., 2010; Hemmers et al., 2011).
Neutrophils isolated from PAD4-deﬁcient mice are unable to cit-
rullinate histones, decondense chromatin, and generate NETs (Li
et al., 2010; Hemmers et al., 2011). Because of their inability to
form NETs, PAD4 KO mice were shown to be more susceptible to
bacterial infection (Li et al., 2010), and, thus, PAD4 is an important
mediator of innate immunity.
Neutrophil elastase, a neutrophil serine protease, resides in the
azurophilic granules and is a component of NETs (Borregaard,
2010; Amulic et al., 2012). The cleavage of microbial virulence fac-
tors by NE is essential for the clearance of speciﬁc Gram-negative
bacteria (Pham, 2006). NE also cleaves histones to drive chro-
matin decondensation during NET formation (Papayannopoulos
et al., 2010). Indeed, NE is essential for the process of NETosis
(Papayannopoulos et al., 2010), and it is interesting to specu-
late that histone citrullination, by PAD4, promotes a relaxing
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of the chromatin structure, allowing NE to gain access. Thus,
the activity of NE and PAD4 may converge upon the chromatin
decondensation process and NET formation. Neutrophils isolated
from PAD4-deﬁcient mice will be useful to delineate the hierarchy
between PAD4 and other molecules, like NE, that are required for
NETosis.
STIMULATION OF PAD4 ACTIVITY
A number of stimuli, including live and heat-killed bacteria, fungi,
protozoa, and chemokines have been reported to induce NET
formation (Guimaraes-Costa et al., 2012). Because NET forma-
tion is PAD4-dependent (Li et al., 2010; Hemmers et al., 2011),
these same stimuli likely also induce PAD4 activation. However,
the activity of PAD4 in relation to each stimuli must be assessed
by looking for citrullination of histones, which is both a hall-
mark of PAD activity (Neeli et al., 2008, 2009) and a component
of NETs (Li et al., 2010; Hemmers et al., 2011). Only a handful
these, including live bacteria, the Gram-negative bacterial cell wall
component lipopolysaccharide (LPS), the Gram-positive bacte-
rial cell wall component lipoteichoic acid (LTA), the fungal cell
wall component zymosan, the proinﬂammatory cytokine TNFα,
and H2O2 have been shown to induce PAD4 activity and histone
citrullination (Neeli et al., 2008, 2009; Li et al., 2010; Hemmers
et al., 2011). As discussed earlier, PAD4 is calcium-dependent, and
it is thought that PAD4 requires calcium levels higher than are
found in the homeostatic cell to be active (Vossenaar et al., 2004).
Not surprisingly, the calcium ionophore ionomycin activates
PAD4 to induce histone citrullination and elicit NET forma-
tion (Neeli et al., 2008, 2009; Wang et al., 2009; Li et al., 2010).
Table 1 catalogs the variety of stimuli reported to stimulate NET
formation.
Although little is known about the downstream signaling path-
ways required for PAD4 activation in neutrophils, cytoskeletal
activity may be involved in PAD4 activation. Pretreatment of cells
with nocodazole or cytochalasin D, which inhibit microtubule
polymerization, prior to LPS stimulation leads to a reduction
of histone citrullination and NET formation (Neeli et al., 2009).
Additionally, blockade of integrin signaling through Mac-1 and
cytohesin-1 impeded PAD4 activity and NET formation (Neeli
et al., 2009). Howcytoskeletal signaling impacts PAD4 is unknown;
however, it has been proposed that the same receptors establish
whether a cell will undergo phagocytosis or NET formation (Neeli
et al., 2009). Indeed, studies have indicated that neutrophils initiate
NET formation when phagocytosis of a large particle fails (Urban
et al., 2006). Perhaps cytoskeletal activity and PAD4-mediated cit-
rullination are linked because the initiation of NET formation
represents a back-up killing mechanism following unsuccessful
phagocytosis.
PAD4 ACTIVITY AND ROS
The generation of reactive oxygen species (ROS) is initiated by
a wide variety of neutrophil stimuli, including phagocytosis of
pathogens and signaling by LPS and TNF (Kohchi et al., 2009),
which are also NET-inducing stimuli. Indeed, ROS generation is
required for NET formation, and, thus, it is likely that ROS gen-
eration is required for PAD4 activation as well. In neutrophils,
superoxide (O•2−) is generated by the NADPH complex (Nox) and
by the electron transport chain in mitochondria (Kohchi et al.,
2009). O•2− is then converted to H2O2 spontaneously or by the
enzyme superoxide dismutase (SOD; Kohchi et al., 2009). H2O2
acts directly on target cells and is converted to additional effec-
tors by enzymes such as myeloperoxidase (MPO). Interestingly,
the addition of H2O2 to primary murine or human neutrophils
induces PAD4-dependent histone citrullination (Neeli et al., 2008;
Li et al., 2010). ROS molecules are highly cytotoxic and act as
antimicrobial agents, but they can also play a dual role as reversible
signal transduction mediators to regulate redox-sensitive target
proteins (Amulic et al., 2012).
The link between ROS and NET formation was ﬁrst recognized
by the fact that patients with chronic granulomas disease (CGD),
who are missing the Nox2 protein essential for NADPH assem-
bly and, thus, cannot form ROS. Neutrophils isolated from CGD
patients do not make NETs in response to S. aureus or phorbol
myristate acetate (PMA; Fuchs et al., 2007). This phenotype is res-
cued by addition of H2O2 or exogenous glucose oxidase, which
generates H2O2 (Fuchs et al., 2007), indicating that the ROS pro-
duction facilitatedbyNox2 is necessary forNETs. Catalase removes
intracellularH2O2 by reduction towater andoxygen (Kohchi et al.,
2009), and catalase inhibition increases intracellularH2O2, leading
to increased NET production in healthy neutrophils (Fuchs et al.,
2007). Subsequent studies have demonstrated that ROSgeneration
is upstream of chromatin decondensation (Remijsen et al., 2011b),
suggesting that NADPH oxidase activation may also be a prereq-
uisite for PAD4 activation. Indeed, LPS-induced citrullination of
histone H4 is decreased when cells are pre-incubated with the
NADPH oxidase inhibitor apocynin (Neeli et al., 2009). Although,
to our knowledge, the activity of PAD4 inCGDneutrophils has not
yet been directly explored, since chromatin decondensation is not
observed in CGD neutrophils, we would predict PAD4-mediated
histone citrullination is also impaired. Since H2O2 treatment can
activate PAD4-mediated histone deimination in primary murine
and human neutrophils (Neeli et al., 2008; Li et al., 2010), and
since NADPH activation seems to be upstream of NET forma-
tion (Neeli et al., 2009), we speculate that PAD4 activation may be
downstream of NADPH (Figure 3).
The contribution of speciﬁc ROS molecules to NET forma-
tion has also been examined. NADPH oxidase or mitochondrial
ROS selective inhibitors established a requirement for NADPH
oxidase generated O•2− (Nishinaka et al., 2011), but excluded
a need for mitochondrial ROS in PMA-induced NET genera-
tion (Kirchner et al., 2012). MPO catalyzes the oxidation of Cl−
ions to generate hypochlorous acid (HOCl) and other reactive
products using H2O2 as a cosubstrate (Arnhold and Flemmig,
2010). In the absence of MPO activity, NET generation is absent
(Papayannopoulos et al., 2010; Metzler et al., 2011; Kirchner et al.,
2012), but this phenotype can be rescued by addition of HOCl
(Palmer et al., 2012). In fact, the HOCl product of MPO has also
been found to be both necessary and sufﬁcient for NET formation,
and in CGD neutrophils, the addition of HOCl is also sufﬁcient to
initiate NET formation (Palmer et al., 2012). Taurine is a cellular
antioxidant capable of reducing HOCl and H2O2 to promote cell
survival (Palmer et al., 2012). Accordingly, preincubation of neu-
trophils with taurine prior to PMA or HOCl stimulation reduces
NET formation (Palmer et al., 2012). Additionally, while SOD
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Table 1 | NET/PAD4 stimuli.
NET stimuli Shown to activate
PAD4
Reference
Activated endothelial cells n.d. Gupta et al. (2010)
Aspergillus fumigatus n.d. Bruns et al. (2010), McCormick et al. (2010)
Candida albicans n.d. Ermert et al. (2009a), Urban et al. (2009), Yost et al. (2009), Hakkim et al. (2010),
Svobodova et al. (2012)
Opsonized Candida albicans n.d. Metzler et al. (2011)
Cryptococcus species n.d. Urban et al. (2009), Springer et al. (2010)
Escherichia coli Yes Grinberg et al. (2008)), Wang et al. (2009), Yost et al. (2009), Yan et al. (2012)
f-MLP Yes Neeli et al. (2008)
H2O2 Yes Neeli et al. (2008), Li et al. (2010)
Haemophilus inﬂuenzae n.d. Juneau et al. (2011)
IL-8+ Shigella ﬂexneri Yes Wang et al. (2009)
IL-81 n.d. Brinkmann et al. (2004), Gupta et al. (2005)
Ca2+ ionophore Yes Wang et al. (2009)
Klebsiella pneumoniae n.d. Papayannopoulos et al. (2010)
Leishmania species n.d. Guimaraes-Costa et al. (2009), Gabriel et al. (2010)
Listeria monocytogenes n.d. Ermert et al. (2009a), Munafo et al. (2009)
LPS Yes Neeli et al. (2008), Li et al. (2010), Munafo et al. (2009)
Lipoteichoic acid Yes Neeli et al. (2009)
Mycobacterium species n.d. Ramos-Kichik et al. (2009)
Nitric Oxide n.d. Patel et al. (2010)
Platelet activating factor n.d. Yost et al. (2009), Fuchs et al. (2010)
Platelet TLR-4 n.d. Clark et al. (2007)
Phorbol-12-myristrate-13-acetate
(PMA)
Yes Brinkmann et al. (2004), Ermert et al. (2009a), Munafo et al. (2009), Neeli et al. (2009),
Chow et al. (2010), Li et al. (2010), Papayannopoulos et al. (2010), Pilsczek et al. (2010),
Lin et al. (2011), Metzler et al. (2011), Remijsen et al. (2011b), Villanueva et al. (2011),
Menegazzi et al. (2012), Palmer et al. (2012), Parker et al. (2012), Yan et al. (2012)
Pseudomonas aeruginosa n.d. Pilsczek et al. (2010)
Salmonella typhimurium n.d. Brinkmann et al. (2004)
Shigella ﬂexneri Yes Brinkmann et al. (2004), Li et al. (2010)
Staphylococcus aureus n.d. Brinkmann et al. (2004), Chow et al. (2010), Pilsczek et al. (2010)
Opsonized Staphylococcus aureus n.d. Palmer et al. (2012)
Staphylococcus epidermidis δ-toxin n.d. Cogen et al. (2010)
Streptococcus species Yes2 Beiter et al. (2006), Buchanan et al. (2006), Lauth et al. (2009), Oehmcke et al. (2009),
Crotty Alexander et al. (2010), Li et al. (2010), Pilsczek et al. (2010)
Streptococcus pneumoniae
α-Enolase
n.d. Mori et al. (2012)
TNFα Yes Neeli et al. (2009), Wang et al. (2009)
Toxoplasma gondii n.d. Abi Abdallah et al. (2012)
Yersinia enterocolitica n.d. Casutt-Meyer et al. (2010)
Zymosan Yes Neeli et al. (2009)
n.d., not determined.
1Some investigators have reported that IL-8-induced NET formation may be sensitive to cell culture conditions (Marcos et al., 2011).
2M1 GAS deﬁcient in an extracellular DNase (Sda1) could induce PAD4-dependent NETs (Li et al., 2010).
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FIGURE 3 | Model of PAD4 activation in NET formation. Pathways that
activate NET formation are less deﬁned than phagocytic pathways, but are
known to require NADPH oxidase activity and the activation of PAD4 and
subsequent histone citrullination. PAD enzymes are Ca2+-dependent.
Since PAD4-mediated histone citrullination is abrogated by the NADPH
inhibitor apocyanin (Neeli et al., 2009), we speculate that NADPH regulated
ROS generation and increase Ca2+ levels may converge to activate PAD4
in neutrophils.
inhibitiondoes not impedeNET formation, additionof exogenous
SOD does seem to increase NET production, perhaps owing to
the increase in available H2O2 (Palmer et al., 2012). These studies
indicate amodel in whichNADPHoxidase activity generates O•2−,
which then dismutates to H2O2 either spontaneously or with the
help of SOD, and is then used by MPO to generate HOCl, which
is necessary and sufﬁcient to induce NET formation. It will be
interesting to determine whether HOCl can also directly regulate
PAD4 activation.
PAD4 AND AUTOPHAGY
Like ROS, autophagy has been shown to be required for chro-
matin decondensation during NET generation (Remijsen et al.,
2011b); however, these two processes seem to be independent of
each other (Remijsen et al., 2011b). Blockade of PI3K with wort-
mannin inhibits autophagy, and pretreatment of PMA stimulated
neutrophils with wortmannin prevented chromatin decondensa-
tion (Remijsen et al., 2011b). However, no direct role between
autophagy, PI3K and citrullination has been shown. Recently,
newly developed PAD4 inhibitors were found to reduce autophagy
processes in an osteosarcoma cell line (Wang et al., 2012), further
providing evidence of a link betweenPAD4 activity and autophagy.
CONCLUSION
Neutrophil extracellular traps have been reported in several patho-
logical scenarios, including SLE, sepsis, thrombosis, and infectious
disease, and may induce or exacerbate inﬂammation through
prolonged inﬂammatory response, tissue damage, and presen-
tation of neo-antigens. Indeed, our group recently described
the PAD4-dependent formation of NETs in a murine model
of the effector phase of RA; however, PAD4 was dispensable
for disease in this model (Rohrbach et al., 2012). Pathology
caused or exacerbated by NETs is an expanding ﬁeld of research.
Because PAD4 is required for NET formation, inhibition of
PAD4 activity may improve clinical outcomes in patients expe-
riencing these inﬂammatory diseases. In fact, PAD inhibitors
have demonstrated efﬁcacy in a variety of immune pathologies
(Chumanevich et al., 2011; Lange et al., 2011; Slack et al., 2011c;
Wang et al., 2012; Willis et al., 2011). Of course, because PAD4 is
required for microbial-induced NET formation (Li et al., 2010;
Hemmers et al., 2011), the side effects of PAD4-targeted ther-
apeutics may also include increased susceptibility to infectious
diseases.
PAD4 is an important component in the innate immune sys-
tem, however its activity has been linked to awide variety of disease
states, including cancer, autoimmunity, and other inﬂammatory
conditions. Despite its signiﬁcance, little is understood about how
the PAD4 enzyme becomes active in order to impart its helpful
and harmful effects. At the protein level, calcium binding, dimer-
ization, and autocitrullination may help regulate its activity. ROS
may also play a role in regulating PAD4 activation (see model in
Figure 3), and recently associations between PAD4 activity and
autophagy have been proposed. Despite these efforts, much is left
to understand about PAD4 enzyme regulation. Anti-PAD4 thera-
pies have been proposed for inﬂammatory conditions and cancer,
thus a more comprehensive understanding of the pathways that
activate PAD4 in neutrophils will be important.
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